Marketing Spending Outpaced R&D in Medicare Negotiations by Drugmakers, Report Shows
Washington, DC – A recent report has shed light on the spending practices of drugmakers involved in Medicare negotiations last year, revealing a startling trend. According to the report, these companies allocated more funds towards shareholder payments and marketing efforts than they did towards research and development. The findings highlight a concerning discrepancy in priorities, raising questions about the motivations driving these financial decisions. With the increasing focus on healthcare costs and accessibility, the revelation …